Piritramide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Piritramide is a synthetic opioid used in the treatment of severe pain.

Generic Name
Piritramide
DrugBank Accession Number
DB12492
Background

Piritramide is under investigation for the treatment of Colon Cancer and Minimal Residual Disease. Piritramide has been investigated for the supportive care of Pain, Postoperative and Postoperative Nausea and Vomiting.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Weight
Average: 430.5851
Monoisotopic: 430.27326173
Chemical Formula
C27H34N4O
Synonyms
  • Piritramida
  • Piritramide
  • Piritramidum
External IDs
  • IDS-NP-013
  • R 3365
  • R-3365

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofSevere pain•••••••••••••••••••••• ••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of adverse effects can be increased when Piritramide is combined with 1,2-Benzodiazepine.
AcetazolamideThe risk or severity of CNS depression can be increased when Acetazolamide is combined with Piritramide.
AcetophenazineThe risk or severity of hypotension and CNS depression can be increased when Acetophenazine is combined with Piritramide.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Piritramide.
AgomelatineThe risk or severity of CNS depression can be increased when Agomelatine is combined with Piritramide.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Dipidolor / Piridolan

Categories

ATC Codes
N02AC03 — Piritramide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as diphenylacetonitriles. These are cyclic aromatic compounds containing a diphenylacetonitrile moiety, which consists of a diphenylmethane linked to and acetonitrile to form 2,2-diphenylacetonitrile.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylacetonitriles
Direct Parent
Diphenylacetonitriles
Alternative Parents
Diphenylmethanes / Alpha amino acid amides / Piperidinecarboxamides / Aralkylamines / Aminopiperidines / Trialkylamines / Primary carboxylic acid amides / Nitriles / Azacyclic compounds / Organopnictogen compounds
show 3 more
Substituents
4-aminopiperidine / Alpha-amino acid amide / Alpha-amino acid or derivatives / Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteromonocyclic compound / Azacycle / Carbonitrile / Carbonyl group
show 18 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
4RP92LYZ2F
CAS number
302-41-0
InChI Key
IHEHEFLXQFOQJO-UHFFFAOYSA-N
InChI
InChI=1S/C27H34N4O/c28-22-26(23-10-4-1-5-11-23,24-12-6-2-7-13-24)14-19-30-20-15-27(16-21-30,25(29)32)31-17-8-3-9-18-31/h1-2,4-7,10-13H,3,8-9,14-21H2,(H2,29,32)
IUPAC Name
1'-(3-cyano-3,3-diphenylpropyl)-[1,4'-bipiperidine]-4'-carboxamide
SMILES
NC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)N1CCCCC1

References

General References
  1. BASG Product Information: Piritramid-hameln (piritramide) solution for injection [Link]
Human Metabolome Database
HMDB0041990
PubChem Compound
9331
PubChem Substance
347828727
ChemSpider
8967
RxNav
8354
ChEBI
135699
ChEMBL
CHEMBL559288
ZINC
ZINC000000538198
Wikipedia
Piritramide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedSupportive CarePost Operative Nausea and Vomiting (PONV) / Postoperative pain1
4CompletedTreatmentColon Cancer / Minimal Residual Disease1
4CompletedTreatmentPostoperative pain1
Not AvailableCompletedTreatmentAnalgesia / Cardiac Diseases / Surgery1
Not AvailableCompletedTreatmentAortic Valve Surgery / Postoperative pain1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntramuscular; Intravenous; Subcutaneous7.5 mg/ml
Injection, solutionIntramuscular; Intravenous7.5 mg/ml
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00998 mg/mLALOGPS
logP3.71ALOGPS
logP3.39Chemaxon
logS-4.6ALOGPS
pKa (Strongest Acidic)15.72Chemaxon
pKa (Strongest Basic)8.87Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area73.36 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity139.81 m3·mol-1Chemaxon
Polarizability49.45 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-008i-4967000000-98351d91fa44f62e846d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-0002900000-c756c166782dfe1c1862
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-01ba-0009000000-edd4ab20cec2e027f203
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-0000900000-9d6306d33bfc31781ed2
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-008c-0968300000-378ee069ee855f8a211f
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0kdj-0009800000-ad41113c97f982a69c20
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-1295000000-34c9f8ec55e4dc3c6030
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-223.7298342
predicted
DarkChem Lite v0.1.0
[M-H]-223.9248342
predicted
DarkChem Lite v0.1.0
[M-H]-203.35986
predicted
DeepCCS 1.0 (2019)
[M+H]+224.1545342
predicted
DarkChem Lite v0.1.0
[M+H]+223.6624342
predicted
DarkChem Lite v0.1.0
[M+H]+205.71785
predicted
DeepCCS 1.0 (2019)
[M+Na]+223.8825342
predicted
DarkChem Lite v0.1.0
[M+Na]+224.1821342
predicted
DarkChem Lite v0.1.0
[M+Na]+212.35698
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 22:35 / Updated at July 03, 2021 01:49